Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $210.00 short put and a strike $200.00 long put offers a potential 11.48% return on risk over the next 35 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $210.00 by expiration. The full premium credit of $1.03 would be kept by the premium seller. The risk of $8.97 would be incurred if the stock dropped below the $200.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 79.86 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Buy Big Biotech — But Not Gilead, Analyst Says
Tue, 12 Nov 2019 16:37:00 +0000
SunTrust initiated most of the big names in biotech with a Buy, but it was less sunny on two of the biggest names in the sector: Gilead Sciences and Regeneron Pharmaceuticals.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
Tue, 12 Nov 2019 13:26:01 +0000
Style Box ETF report for FTCS
Drugmaker Amgen cuts a quarter of its Kendall Square research staff
Mon, 11 Nov 2019 17:51:49 +0000
The layoffs come just a few years after the California-based pharmaceutical company kicked off an expansion in New England.
Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio
Mon, 11 Nov 2019 14:00:00 +0000
THOUSAND OAKS, Calif., Nov. 11, 2019 /PRNewswire/ — Amgen (AMGN) today announced that new data from its cardiovascular portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia, Nov. 16-18. This includes new clinical and real-world studies that provide further evidence of the benefits of intensive lipid-lowering therapy with Repatha® (evolocumab) as well as new data for omecamtiv mecarbil, a novel selective cardiac myosin activator being developed for the treatment of heart failure with reduced ejection fraction (HFrEF). “The Amgen clinical and real-world data being presented at AHA highlights our ongoing commitment to further the cardiovascular community's understanding of Repatha's role in lowering high LDL-C, one of the most important modifiable risk factors associated with an increased risk of heart attack,”1 said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
Amgen at 52-Week Highs Bumps Against Resistance, Remains a Long-Term Hold
Mon, 11 Nov 2019 12:04:00 +0000
Shares of biopharma giant Amgen have rallied more than 30% since their summer lows and recently hit all-time highs. Investors should now be cautious in the short term due to a strong fundamental resistance level.
Also on Market Tamer…
Follow Us on Facebook